Publication

The state and consequences of dermatology drug prices in the United States

Albrecht, Joerg
Maloney, Mary E.
Brod, Bruce Alan
Embargo Expiration Date
Abstract

In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.

Source

J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1016/j.jaad.2016.03.053
PubMed ID
27423978
Other Identifiers
Notes

Full author list omitted for brevity. For full list of authors see article.

Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Distribution License